Neuroscience company with exciting potential
This brain health software group, specialising in digital products to advance clinical research and patient treatment, has reported a much improved order book and sales piplene. Shareholders will need to be patient, but the valuation of this small company with innovative technology looks appealing.
According to the World Health Organisation, disorders of the brain, such as Alzheimer’s disease, Schizophrenia, Parkinson’s, depression and mental illness, are the world’s primary cause of ill health, resulting in higher costs and more hospitalisations than any other disease group. Early diagnosis of brain illnesses is desirable as it can help to reduce the costs associated with Alzheimer’s disease and dementia. Cambridge Cognition (AIM: COG) is a highly innovative AIM listed digital health technology company, committed to enhancing global research, accelerating treatment development and improving patient outcomes in conditions affecting brain health by optimising the assessment of cognition. Based on science and technology…